- Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
-
Viljoen A, Bain SC
- KMID: 2539814
- Endocrinol Metab.
- 2023 Feb;38(1):25-33.
- doi: 10.3803/EnM.2022.1642
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness... -
- CITED
-
- Close
- SHARE
-
- Close
- The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
-
Jakubowska A, Roux CWl, Viljoen A
- KMID: 2552791
- Endocrinol Metab.
- 2024 Feb;39(1):12-22.
- doi: 10.3803/EnM.2024.1942
Obesity is the fifth leading risk factor for global deaths with numbers continuing to increase worldwide. In the last 20 years, the emergence of pharmacological treatments for obesity based on... -
- CITED
-
- Close
- SHARE
-
- Close
